In this issue of Blood Cancer Discovery, Kotini and colleagues present a strategy for large scale reprogramming of primary human AMLs to iPSCs. They show that hematopoietic differentiation of AML iPSCs gives rise to transplantable leukemias with remarkable molecular similarity to the original patients' AML, providing new models and insights into disease.
Keyphrases
- induced pluripotent stem cells
- acute myeloid leukemia
- end stage renal disease
- bone marrow
- chronic kidney disease
- endothelial cells
- newly diagnosed
- ejection fraction
- small molecule
- papillary thyroid
- prognostic factors
- squamous cell carcinoma
- allogeneic hematopoietic stem cell transplantation
- patient reported outcomes
- squamous cell
- single molecule
- childhood cancer
- acute lymphoblastic leukemia
- lymph node metastasis